TB-500 vs BPC-157: How the Two Healing Peptides Differ

By DoseGauge Editorial · Updated 2026-06-14 · 7 min read

TB-500 and BPC-157 are two different research peptides often discussed together for tissue repair, but they differ in origin and mechanism. TB-500 is a synthetic fragment of thymosin beta-4, a natural cellular protein, studied for angiogenesis and cell migration. BPC-157 is a synthetic peptide derived from a body-protective compound identified in gastric juice, studied for angiogenesis and tendon and fibroblast effects, and often described as more locally acting. Both are research peptides, neither is FDA-approved, evidence for both is largely preclinical, and TB-500 is banned in sport by the World Anti-Doping Agency. This page describes the differences. It does not recommend either peptide, any dose, or any provider.

Origin and what each is

The clearest way to separate these two peptides is by where each one comes from. They share a research theme (tissue repair) but originate from entirely different parent molecules.

TB-500 is a synthetic heptapeptide fragment, the sequence Ac-LKKTETQ, derived from thymosin beta-4 (TB4), a naturally occurring 43-amino-acid protein found in many mammalian tissues. The published reviews study thymosin beta-4, the full parent protein, and describe it as a small secreted peptide built around a central actin-binding domain (Maar et al., 2021; Xing et al., 2021). TB-500 reproduces only part of that sequence, so it is best read as a fragment of thymosin beta-4, not the whole protein. For more on that distinction, see what tb-500 is.

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It is not a fragment of thymosin beta-4 and has no relation to that protein. Its evidence base is, like TB-500's, almost entirely preclinical (cell-culture and animal studies), with very limited human data. So while both are short synthetic peptides studied for tissue repair, their starting points are unrelated: one traces to a cellular structural protein, the other to a compound identified in gastric juice.

Mechanism as studied

The two peptides are associated with overlapping research themes, especially angiogenesis, but the mechanisms attributed to each in the literature are described differently.

For TB-500, the proposed mechanisms come from research on thymosin beta-4, the parent protein, and are largely preclinical. A central one is actin binding: the reviews describe thymosin beta-4 as an actin-sequestering peptide that helps regulate actin filament assembly, which supports cell migration (Maar et al., 2021; Xing et al., 2021). From there the literature describes roles in angiogenesis, with thymosin beta-4 reported to upregulate VEGF expression and act through signaling pathways such as PI3K/Akt/eNOS, alongside effects on wound healing and inflammation in injury models (Xing et al., 2021). Because thymosin beta-4 is a widely distributed cellular protein, its reported effects are often discussed as relatively systemic.

BPC-157 is associated in its own literature with angiogenesis and with effects on tendon and fibroblast cells, and it is frequently described as acting more locally at a site of injury. The two peptides therefore share an angiogenesis theme but are characterized differently in emphasis: the thymosin beta-4 work centers on actin binding and cell migration across many tissues, while BPC-157 is more often framed around localized tendon and fibroblast effects. In both cases these are mechanisms reported in preclinical research, not outcomes established for either peptide in people.

Comparison table

Evidence and status: both are research peptides

For all the discussion that surrounds them, the two peptides sit in the same evidentiary position. The evidence base for each is largely preclinical: cell-culture and animal studies, with human outcome data essentially absent. No controlled human trial has established that either peptide produces a given clinical benefit, and neither has a validated human pharmacokinetic profile in the peer-reviewed literature.

Neither is FDA-approved for any indication. TB-500 carries an additional status that BPC-157 does not: it is prohibited at all times in sport under the World Anti-Doping Agency Prohibited List, category S2.3 (Growth Factors and Related Substances), so a competitive athlete who tests positive is subject to sanction regardless of intent. None of that amounts to an established safety or efficacy profile in humans for either compound. This page describes what the literature reports and does not claim either peptide is safe, effective, or appropriate for any purpose. Whether any research peptide is appropriate is a decision for a licensed clinician.

Using them together is a separate question

People often combine BPC-157 and TB-500 because both have been studied preclinically for tissue-repair effects. That is a different topic from comparing them, and it comes with its own caveats. There is no established blend dose: no controlled human trial has evaluated a fixed BPC-157 plus TB-500 combination, so no evidence-based dose ratio exists, and researchers who work with both calculate each peptide separately from its own vial concentration. This comparison page does not cover blend dosing or recommend a stack. For that use case, see the BPC-157 and TB-500 stack guide.

This page is informational and educational only. It is not medical advice, and it does not recommend either peptide, any dose, or any provider. Consult a licensed clinician before using any research peptide.

Frequently asked questions

Is TB-500 or BPC-157 better for healing?

This page does not rate one as better. Both are research peptides with evidence that is largely preclinical (cell and animal studies) and no human outcome trials establishing a healing benefit. Neither is FDA-approved for any indication, and TB-500 is also banned in sport by WADA. "Better" depends on context that no controlled human comparison has settled, which is a conversation for a licensed clinician, not a calculator.

What is the difference between TB-500 and BPC-157?

They differ mainly in origin and how their mechanisms are described. TB-500 is a synthetic fragment (Ac-LKKTETQ) of thymosin beta-4, a natural 43-amino-acid protein, with reported mechanisms centered on actin binding, cell migration, and angiogenesis (Xing et al., 2021; Maar et al., 2021). BPC-157 is a synthetic 15-amino-acid peptide derived from a body-protective compound identified in gastric juice, studied for angiogenesis and tendon and fibroblast effects and often described as more locally acting. Both are research peptides studied largely in preclinical models.

Can you take TB-500 and BPC-157 together?

The two are often combined in research and community settings, but there is no established blend dose and no controlled human trial of a fixed combination, so no evidence-based ratio exists. Describing that the pairing exists is not a recommendation to use it. Researchers who work with both calculate each peptide separately from its own vial concentration. The dedicated BPC-157 and TB-500 stack guide covers that topic; whether any combination is appropriate is a decision for a licensed clinician.

Are TB-500 and BPC-157 FDA-approved?

No. Neither TB-500 nor BPC-157 is approved by the FDA for any indication. Both are research peptides with evidence bases that are largely preclinical and with very limited human data. TB-500 is additionally prohibited at all times in sport under the World Anti-Doping Agency Prohibited List (category S2.3). Consult a licensed clinician before using any research peptide.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.